Clinical trials: Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease
Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)
This study will investigate if a medication (metformin) widely used in the treatment of diabetes could be re-purposed for the treatment of patients with a diagnosis of early stage ADPKD to slow the rate of kidney function…
- Trial name
- NCT04939935
- Testing
- Metformin XR, Control
- Where
- 49 sites in Australia, New Zealand and 1 more
- Volunteers
- 1,174 people
- Sponsor
- The University of Queensland
Autosomal Dominant Polycystic Kidney Disease
Clinical Implications of DNA Analysis on ADPKD
Autosomal dominant polycystic kidney disease (ADPKD) is an inherited disease. We plan DNA analysis using the next generation sequencer (NGS) and examine the relationship between mutational types and clinical phenotypes.
- Trial name
- DNAAA (NCT02322385)
- Where
- 2 sites in Japan
- Volunteers
- 80 people
- Sponsor
- Kyorin University
Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease
ARPKD Database Study
Hepato-renal fibrocystic diseases (HRFD) is a term developed that encompasses rare diseases such as Autosomal Recessive Polycystic Kidney Disease (ARPKD), and other diseases with common features (Joubert syndrome, Bardet Biedl…
- Conditions
- Hepato/Renal Fibrocystic Disease, Autosomal Recessive Polycystic Kidney Disease, Joubert Syndrome, Bardet Biedl Syndrome
- Trial name
- ARPKD (NCT01401998)
- Where
- 6 sites in United States
- Volunteers
- 200 people
- Sponsor
- Children's Hospital of Philadelphia
Autosomal Dominant Polycystic Kidney, ADPKD
Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
The goal of the study was to compare and evaluate safety and efficacy of tesevatinib 50 milligrams (mg) versus placebo in participants with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT03203642
- Testing
- Tesevatinib
- Where
- 19 sites in United States
- Volunteers
- 80 people
- Sponsor
- Kadmon, a Sanofi Company
Polycystic Kidney Disease, Assisted Reproductive Technology
Descriptive Analysis of Preimplantation Genetic Test (PGT)in Couples With Polycystic Kidney Disease (PKD). In the ADPKD Subgroup Evaluation of Outcomes and Complications Comparing Couples in Which the Father is Affected With Couples in Which the Mother is Affected
The goal of this observational study is to evaluate the outcomes of assisted reproductive technology (ART) combined with preimplantation genetic testing for monogenic diseases (PGT-M) in couples affected by or carriers of…
- Conditions
- Polycystic Kidney Disease, Assisted Reproductive Technology, Preimplantation Genetic Testing (PGT)
- Trial name
- PGT-M PKD (NCT07310641)
- Testing
- Assisted reproductive technology and preimplantation diagnosis for monogenic diseases
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Azienda Sanitaria Universitaria Integrata del Trentino
Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease
Octreotide in Severe Polycystic Liver Disease
This study will evaluate the effect of Octreotide LAR® on the liver volumes of patients with severe polycystic liver disease who are not candidates or decline surgical treatments such as liver cyst fenestration, liver resection…
- Conditions
- Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly, Liver Diseases
- Trial name
- NCT00426153
- Testing
- Octreotide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Mayo Clinic
Polycystic Kidney, Autosomal Dominant
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
The purpose of the trial was to evaluate and describe the long term safety of tolvaptan in participants with autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02251275
- Testing
- Tolvaptan
- Where
- 210 sites in United States, Argentina and 18 more
- Volunteers
- 1,803 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Autosomal Dominant Polycystic Kidney, Obesity
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
The proposed clinical trial aims to assess if a year of treatment with a glucagon-like peptide 1 receptor agonist, a medication approved for weight management that also improves the body's response to glucose and insulin, can…
- Trial name
- NCT06582875
- Testing
- Tirzepatide
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- University of Colorado, Denver
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
- Trial name
- AGLOW (NCT07161037)
- Testing
- VX-407
- Where
- 43 sites in United States, Belgium and 6 more
- Volunteers
- 26 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
The purpose of the study is to evaluate the safety, tolerability and pharmacokinetics of VX-407 in healthy participants.
- Trial name
- NCT07022119
- Testing
- VX-407
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Autosomal Dominant Polycystic Kidney Disease
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
The investigators multicenter randomized open-labelled study will investigate the efficacy of an everolimus based immunosuppression in reducing total native kidney volume in kidney recipients with autosomal dominant polycystic…
- Trial name
- EVERKYSTE (NCT02134899)
- Testing
- Everolimus, Calcineurin inhibitors maintenance
- Where
- France
- Volunteers
- 3 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis
National Registry of Rare Kidney Diseases
The goal of this National Registry is to is to collect information from patients with rare kidney diseases, so that it that can be used for research.
- Conditions
- Adenine Phosphoribosyltransferase Deficiency, AH Amyloidosis, AHL Amyloidosis, AL Amyloidosis
- Trial name
- RaDaR (NCT06065852)
- Where
- United Kingdom
- Volunteers
- 35,000 people
- Sponsor
- UK Kidney Association
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Diet as a Potential Treatment for Autosomal Dominant Polycystic Kidney Disease
The purpose of this study is to learn if dietary habits can affect vasopressin secretion in patients with autosomal dominant polycystic kidney disease.
- Trial name
- NCT02225860
- Testing
- Diet and water adjustment
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Tufts Medical Center
Autosomal Dominant Polycystic Kidney Disease
NOX4 and Related Biomarkers in ADPKD
To determine the value of NOX4, markers of mitochondria injury and function, and oxidative stress as real-time biomarkers to assess disease severity in patients with early autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT04630613
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Mayo Clinic
Autosomal Dominant Polycystic Kidney Disease
ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common genetic cause of kidney disease that causes fluid-filled cysts to develop in the kidneys.
- Trial name
- ANCHOR (NCT06902558)
- Testing
- ABBV-CLS-628
- Where
- 91 sites in United States, Australia and 10 more
- Volunteers
- 240 people
- Sponsor
- Calico Life Sciences LLC
Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases
Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease
Polycystic Kidney Disease (PKD) is the most common genetic disease leading to End Stage Kidney Disease (ESKD), affecting between 1 in 500-1000 individuals from every ethnic group.
- Trial name
- NCT05870007
- Testing
- Atorvastatin 20 Mg Oral Tablet, Sodium Bicarbonate 600 Mg Oral Tablet
- Where
- 3 sites in Taiwan
- Volunteers
- 30 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Autosomal Dominant Polycystic Kidney Disease
Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy
Currently the only approved use for rapamycin (sirolimus) is for immunosuppression after renal transplantation. This trial is designed to determine whether rapamycin is safe and effective treatment for patients with polycystic…
- Trial name
- NCT00920309
- Testing
- Rapamycin
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Yale University
Polycystic Kidney Diseases
Study and Management of Cystic Complications in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease is characterised by the development of renal and hepatic cysts. While the main complication is chronic end-stage renal failure, specific cyst-related complications are common…
- Trial name
- COMPLIK (NCT06036992)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- University Hospital, Brest
ADPKD
Genetic Testing in Autosomal Dominant Polycystic Kidney Disease
Individuals with a diagnosis of autosomal dominant polycystic kidney disease (ADPKD) often have a family history of the condition although up to 10-15% of cases are sporadic mutations.
- Trial name
- NCT06085807
- Testing
- Survey
- Where
- United States
- Volunteers
- 226 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Kidney, Polycystic, Autosomal Dominant
CCB Safety Study in Treatment of Hypertension of ADPKD
This study examines the safety and efficacy of calcium channel blocker (CCB) in the treatment of hypertension of Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients.
- Trial name
- NCT00541853
- Testing
- Candesartan, Candesartan and Cilnidipine, Candesartan plus non-CCB agents
- Where
- 6 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Kyorin University